The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both injection and nasal delivery that use Aegis’s Intravail and ProTek excipients. Both patents have been licensed to Azelon Pharmaceuticals.
Aegis says that it anticipates that it will be granted additional patents for Intravail and ProTek formulations of other drugs. The company is looking to license formulaitons of human growth hormone; GLP-1 analogs; alpha, beta, and gamma interferon; and others.
Read the Aegis press release.
